SecBot SecBot
8-K ·Filed Jun 2, 2026

ONCY

ONCOLYTICS BIOTECH INC
NEUTRAL
Impact 2/10
Horizonmonths Processed5mo ago SEC0001129928-26-000039
8-K context-dependent: Items 5.02, 8.01
Actionable Insight • Neutral

Monitor for any future partnership or clinical milestones; the board addition and COO promotion suggest a focus on operational execution and strategic transactions, but the filing itself contains no near-term catalyst.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.9300
T+0 close · Jun 2, 2026 · via day close
Latest settled
−8.00%
T+60 · $0.8556
Vs SPY
−9.12%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 2 $0.9300entry
  2. T+1 · 6mo ago −5.38%α −4.68% · $0.8800
  3. T+5 · 5mo ago −12.90%α −9.94% · $0.8100
  4. T+20 · 5mo ago −3.15%α −1.59% · $0.9007
  5. T+60 · 3mo ago −8.00%α −9.12% · $0.8556
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Oncolytics Biotech announced the appointment of Stephen Glover to its Board of Directors and the promotion of John McAdory to Chief Operating Officer. This is a routine organizational change with no material financial impact.

Key Facts

  • Stephen Glover appointed as independent director, granted option to purchase 96,000 shares vesting over 3 years.
  • John McAdory promoted to COO, previously EVP of Strategy and Operations; no additional compensation.
  • Glover brings public company board and M&A experience, including chairing Ambrx during its $2B acquisition by J&J.

Financial Impact

No financial figures disclosed; director option grant is standard compensation.

Risk Factors

  • No material risks identified from this filing.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
75% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001129928-26-000039
Document: oncybodandcoo.htm0001129928-26-000039
Document: 0001129928-26-000039-index-headers.html0001129928-26-000039
Document: 0001129928-26-000039-index.html0001129928-26-000039
Document: 0001129928-26-000039.txt0001129928-26-000039

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 2, 2026